Table 3 Summary of efficacy results for better and poorer efficacy subgroups by treatment arms
Better efficacy subgroup | Poor efficacy subgroup | |||
|---|---|---|---|---|
FOLFIRI-placebo | FOLFIRI-aflibercept | FOLFIRI-placebo | FOLFIRI-aflibercept | |
Overall survival rates | ||||
6 months | 83% | 88% | 71% | 70% |
12 months | 54% | 64% | 43% | 42% |
18 months | 34% | 46% | 24% | 24% |
24 months | 22% | 35% | 12% | 15% |
30 months | 12% | 27% | 10% | 13% |
Progression free survival rates | ||||
6 months | 38% | 63% | ||
12 months | 15% | 20% | ||
18 months | 5% | 6% | ||
Objective response rates | ||||
11% | 24% | |||